Covid-19 Banner

NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx® Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs

The RADx® Tech and ATP programs are supporting late-stage development of innovative point-of-care, home-based tests, and clinical laboratory tests.

Summary data on proposals submitted to the RADx® Tech and ATP Programs.

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

Listing of COVID-19 related grants funded by NIBIB.

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.


View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADx® Tech/ATP programmatic or technical inquiries:

All other RADx® Tech/ATP Applicants:

SBIR/STTR Applicants:

All others:

Related News

April 20, 2022
Two recent studies supported by the National Institutes of Health Rapid Acceleration of Diagnostics (RADx) Tech program demonstrate how widespread distribution of COVID-19 at-home antigen tests can be used as an effective public health strategy to reduce the spread of the disease. Source: UMass Chan
April 19, 2022
A new type of COVID-19 test is hitting the market, and could change how we detect the virus. MicroGEM, a Virginia-based molecular biology company with a Charlottesville office, is using its new saliva test to track COVID-19. Source: NBC TV12 Richmond, Virginia.
April 12, 2022
An NIH-funded team at Cornell University has developed a compound delivered into the nose that blocked a protein used by SARS-CoV-2 to get into cells and prevented severe infection in mice. Antiviral drugs that target host cells may work against many existing and future variants of the virus that causes COVID-19. Source: NIH Research Matters
March 17, 2022
A small preliminary study from Northwestern Medicine has shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19. The finding builds on another study with similar results and could have implications in how physicians screen for and address high-risk pregnancies.
March 16, 2022
A new rapid PCR COVID-19 test invented by Northwestern University faculty and Minute Molecular Diagnostics has received FDA emergency use authorization.